VRTX - The Upcoming Calithera Cystic Fibrosis Data Could Be Significant

• Calithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis.
• We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference.
• A positive read-out here could see a very strong stock appreciation, which currently the market may be overlooking.

For further details see: